Nintedanib is an anti-fibrotic agent for IPF, systemic sclerosis-induced interstitial lung disease (SSc-ILD), and progressive fibrosing interstitial lung disease (PF-ILD) that inhibits the vascular endothelial growth factor (VEGF)-2, platelet-derived growth factor, and fibroblast growth factor receptors13,14. Here, VEGFA is linked to interstitial lung disease.